Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects

Chikungunya Virus Clinical Trial

Official title:
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region

Status Completed

Clinical Trial Summary

This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03325075
Study type	Interventional
Source	ModernaTX, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	August 15, 2017
Completion date	November 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05072080` - A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317	Phase 3
Completed	`NCT05065983` - A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine	Phase 2
Terminated	`NCT00391313` - CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease	Phase 3
Completed	`NCT05349617` - Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years	Phase 3
Completed	`NCT02305732` - A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
Completed	`NCT01489358` - Chikungunya Virus Vaccine Trial in Healthy Adults	Phase 1